Experimental drug N-PPG shows promise for rare, untreatable kidney stone disease

Primary hyperoxaluria type 2 causes progressive kidney failure in infants and young adults, often requiring kidney and liver transplantation to extend survival.

In the quiet corridors of a research institute, two scientists from unrelated fields stumbled into a discovery that may rewrite the fate of patients born with a disease that has never had a treatment. A small molecule called N-PPG, originally explored for cancer and neurodegeneration, has now demonstrated the ability to completely prevent kidney failure and restore normal survival in mice with primary hyperoxaluria type 2 — a rare genetic disorder that currently leaves roughly 1,700 Americans with no options beyond transplant or dialysis. The finding, published in Kidney International, reminds

Experimental drug N-PPG shows promise for rare, untreatable kidney stone disease

Cobertura Relacionada

Receba o Register no seu e-mail